In vivo imaging of cerebral serotonin transporter and serotonin 2A receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") and hallucinogen users

Archives of General Psychiatry

Volumn 68, Issue 6, 2011, Pages 562-576

  Erritzoe, David ^a,b,e   Frokjaer, Vibe G ^a,b   Holst, Klaus K ^b   Christoffersen, Maria ^a,b   Johansen, Sys S ^c   Svarer, Claus ^a,b   Madsen, Jacob ^a   Rasmussen, Peter M ^d   Ramsøy, Thomas ^b,f   Jernigan, Terry L ^b,f,g   Knudsen, Gitte M ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f HVIDOVRE HOSPITAL   (Denmark)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 [2 [(DI(METHYL)AMINO)METHYL]PHENYL]SULFANYLBENZONITRILE C 11; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ALPHA METHYLSEROTONIN; ALTANSERIN F 18; AMPHETAMINE; CANNABIS; COCAINE; KETAMINE; LYSERGIDE; N,N DIMETHYLTRYPTAMINE; PSILOCYBINE; PSYCHEDELIC AGENT; RADIOPHARMACEUTICAL AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IN VIVO STUDY; MALE; MESENCEPHALON; NEOCORTEX; NEOSTRIATUM; POSITRON EMISSION TOMOGRAPHY; PSYCHOLOGIC ASSESSMENT; RECEPTOR BINDING; SUBSTANCE ABUSE;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANILINE COMPOUNDS; BRAIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HALLUCINOGENS; HUMANS; KETANSERIN; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SULFIDES;

EID: 79958027356     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.56     Document Type: Article

References (96)

1. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2008. Bethesda, MD: National Institutes of Health; 2009.
2. Gotz W. The State of the Drug Problem in Europe: Annual Report 2008. Lissabon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2008.
3. Nutt D. MDMA ("Ecstasy"): A Review of Its Harms and Classification Under the Misuse of Drugs Act 1971: Advisory Council on the Misuse of Drugs. London, England: ACMD; 2008.
4. Capela JP, Carmo H, Remião F, Bastos ML, Meisel A, Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol. 2009;39(3):210-271.
5. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA(3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol. 1988;149(1-2):159-163.
6. 2A receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53(3):439-452.
7. Blakely RD, De Felice LJ, Hartzell HC. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol. 1994;196:263-281.
8. Battaglia G, Yeh SY, De Souza EB. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav. 1988;29(2):269-274. (Pubitemid 19258259)
9. Battaglia G, Sharkey J, Kuhar MJ, de Souza EB. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse. 1991;8(4):249-260.
10. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS. Methylenedioxy-methamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period: part II: radioligand binding and autoradiography studies. J Pharmacol Exp Ther. 1996;276(2):855-865.
11. Axt KJ, Mullen CA, Molliver ME. Cytopathologic features indicative of 5-hydroxy-tryptamine axon degeneration are observed in rat brain after administration of d- and l-methylenedioxyamphetamine. Ann N Y Acad Sci. 1992;648:244-247.
12. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci. 1990;600:649-664.
13. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci. 1995;15(8):5476-5485.
14. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci. 1999;19(12):5096-5107. (Pubitemid 29270144)
15. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA. In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse. 1998;29(2):183-192. (Pubitemid 28221796)
16. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA. Serotonergic recovery after (±)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther. 1993;264(3):1484-1491. (Pubitemid 23318648)
17. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet. 2001; 358(9296):1864-1869. (Pubitemid 34008653)
18. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med. 2003;44(3):375-384. (Pubitemid 39586013)
19. 11C]DASB. Neuropsychopharmacology. 2005;30(9):1741-1750.
20. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, Ramsey NF, Heeten GJ, van den Brink W. Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry. 2008;193(4):289-296.
21. Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[11C]DASB and structural brain imaging study. Brain. 2010;133(pt 6):1779-1797.
22. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988;8(8):2788-2803.
23. Berman S, O'Neill J, Fears S, Bartzokis G, London ED. Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci. 2008;1141:195-220.
24. Cowan RL. Neuroimaging research in human MDMA users: a review. Psychopharmacology (Berl). 2007;189(4):539-556. (Pubitemid 44791223)
25. Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 2003;69(2):109-119. (Pubitemid 36259773)
26. Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry. 2005;58(8):624-631. (Pubitemid 41565577)
27. Halpern JH. Hallucinogens: an update. Curr Psychiatry Rep. 2003;5(5):347-354. (Pubitemid 38899228)
28. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131-181. (Pubitemid 38167565)
29. Capela JP, Ruscher K, Lautenschlager M, Freyer D, Dirnagl U, Gaio AR, Bastos ML, Meisel A, Carvalho F. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience. 2006;139(3):1069-1081.
30. 2A-receptor stimulation in cortical neurons. Neurotoxicology. 2007;28(4):868-875.
31. Shioda K, Nisijima K, Yoshino T, Kuboshima K, Iwamura T, Yui K, Kato S. Risperi-done attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats. Neurotoxicology. 2008;29(6):1030-1036.
32. 2 antagonist ketanserin in healthy humans. Neuropsychopharmacology. 2000;23(4):396-404.
33. 2A receptors in rat and human brain. Neuropsychopharmacology. 2002;26(3):387-396.
34. 2B/C receptors regulate 5-HT cell firing in the dorsal raphe nucleus of the anaesthetised rat. Br J Pharmacol. 2003;139(5):998-1004.
35. Rattray M, Baldessari S, Gobbi M, Mennini T, Samanin R, Bendotti C. p-Chlorphenylalanine changes serotonin transporter mRNA levels and expression of the gene product. J Neurochem. 1996;67(2):463-472. (Pubitemid 26255638)
36. Rothman RB, Jayanthi S, Wang X, Dersch CM, Cadet JL, Prisinzano T, Rice KC, Baumann MH. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse. 2003;50(3):233-239. (Pubitemid 37315353)
37. Dewar KM, Grondin L, Carli M, Lima L, Reader TA. [3H]Paroxetine binding and serotonin content of rat cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region following p-chlorophenylalanine and p-chloroamphetamine treatment. J Neurochem. 1992;58(1):250-257.
38. Brown SA, Myers MG, Lippke L, Tapert SF, Stewart DG, Vik PW. Psychometric evaluation of the Customary Drinking and Drug Use Record (CDDR): ameasure of adolescent alcohol and drug involvement. J Stud Alcohol. 1998;59(4):427-438. (Pubitemid 28272663)
39. Skinner HA, Sheu WJ. Reliability of alcohol use indices: the Lifetime Drinking History and the MAST. J Stud Alcohol. 1982;43(11):1157-1170. (Pubitemid 13082703)
40. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47(6):589-593. (Pubitemid 20189971)
41. Department of Forensic Chemistry, Aarhus University. What do ecstasy tablets contain? surveillance of seized ecstasy tablets in Denmark [in Danish]: report for the Danish National Board of Health. http://www.sst.dk/Udgivelser. aspx; 2007. Accessed 2009.
42. Johansen SS, Jornil J. Determination of amphetamine, methamphetamine, MDA and MDMA in human hair by GC-EI-MS after derivatization with perfluorooctanoyl chloride. Scand J Clin Lab Invest. 2009;69(1):113-120.
43. 18F]altanserin- PET and the bolus/infusion approach. J Cereb Blood Flow Metab. 2003;23(8):985-996.
44. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23(9):1096-1112.
45. Erritzoe D, Frokjaer VG, Haugbol S, Marner L, Svarer C, Holst K, Baaré WF, Rasmussen PM, Madsen J, Paulson OB, Knudsen GM. Brain serotonin 2A receptor binding: relations to body mass index, tobacco and alcohol use [published correction appears in Neuroimage. 2009;47(2):780]. Neuroimage. 2009;46(1):23-30.
46. Frokjaer VG, Vinberg M, Erritzoe D, Svarer C, Baaré W, Budtz-Joergensen E, Madsen K, Madsen J, Kessing LV, Knudsen GM. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage. 2009;46(2):360-366.
47. Jovicich J, Czanner S, Greve D, Haley E, van der Kouwe A, Gollub R, Kennedy D, Schmitt F, Brown G, Macfall J, Fischl B, Dale A. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30(2):436-443.
48. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87-97. (Pubitemid 128742012)
49. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbøl S, Frøkjaer VG, Holm S, Paulson OB, Knudsen GM. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24(4):969-979. (Pubitemid 40164499)
50. Erritzoe D, Holst K, Frokjaer VG, Licht CL, Kalbitzer J, Nielsen FA, Svarer C, Madsen J, Knudsen G. A nonlinear relationship between cerebral serotonin transporter and 5-HT(2A) receptor binding: an in vivo molecular imaging study in humans. J Neurosci. 2010;30(9):3391-3397.
51. Pazos APA, Probst A, Palacios JM. Serotonin receptors in the human brain, IV: autoradiographic mapping of serotonin-2 receptors. Neuroscience. 1987;21(1):123-139. (Pubitemid 17076867)
52. 3H]paroxetine. Neuroscience. 1988;27(2):473-496.
53. Kish SJ, Furukawa Y, Chang LJ, Tong J, Ginovart N, Wilson A, Houle S, Meyer JH. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol. 2005;32(2):123-128. (Pubitemid 40260663)
54. Kalbitzer J, Erritzoe D, Holst KK, Nielsen FA, Marner L, Lehel S, Arentzen T, Jernigan TL, Knudsen GM. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychol. 2010;67(11):1033-1039.
55. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH. Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry. 2008;65(9):1072-1078.
56. 2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage. 2004; 21(3):1105-1113.
57. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry. 2001; 158(11):1843-1849. (Pubitemid 33054777)
58. 11C]DASB is affected by serotonin transporter genotype. J Neural Transm. 2007;114(5):635-639.
59. 123I-β-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med. 2000;41(1):36-44.
60. Holst K. gof: Model-diagnostics based on cumulative residuals. R package version 0.6-4. http://www.r-project.org. Accessed April 16, 2009.
61. Ritz C, Streibig JC. Bioassay analysis using R. J Stat Softw. 2005;12(5):1-22. http://www.jstatsoft.org/v12/i05/paper. Accessed August 1, 2009. (Pubitemid 40218001)
62. Erritzoe D, Holst K, Frokjaer VG, Licht CL, Kalbitzer J, Nielsen FA, Svarer C, Madsen J, Knudsen G. A nonlinear relationship between cerebral serotonin transporter and 5-HT2A receptor binding: an in vivo molecular imaging study in humans. J Neurosci. 2010;30(9):3391-3397.
63. Reneman L, Booij J, Majoie CB, Van Den Brink W, Den Heeten GJ. Investigating the potential neurotoxicity of ecstasy (MDMA): an imaging approach. Hum Psychopharmacol. 2001;16(8):579-588. (Pubitemid 34036938)
64. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain. 2008;131(pt 11):2936-2945.
65. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet. 1998;352(9138):1433-1437. (Pubitemid 28510877)
66. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry. 1999;175:63-69. (Pubitemid 29307857)
67. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M. A voxel-based PET investigation of the long-term effects of "ecstasy" consumption on brain serotonin transporters. Am J Psychiatry. 2004;161(7):1181-1189.
68. Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P, Curran HV, Grasby P. Brain serotonin transporter binding in former users of MDMA ("ecstasy"). Br J Psychiatry. 2009;194(4):355-359.
69. Buchert R, Thomasius R, Petersen K, Wilke F, Obrocki J, Nebeling B, Wartberg L, Zapletalova P, Clausen M. Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging. 2006;33(2):188-199. (Pubitemid 43152887)
70. Kim JS, Ichise M, Sangare J, Innis RB. PET imaging of serotonin transporters with [11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med. 2006;47(2):208-214. (Pubitemid 46780884)
71. Cumming P, Møller M, Benda K, Minuzzi L, Jakobsen S, Jensen SB, Pakkenberg B, Stark AK, Gramsbergen JB, Andreasen MF, Olsen AK. A PET study of effects of chronic 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on serotonin markers in Göttingen minipig brain. Synapse. 2007;61(7):478-487. (Pubitemid 46753967)
72. Kovács GG, Andó RD, Adori C, Kirilly E, Benedek A, Palkovits M, Bagdy G. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathol Appl Neurobiol. 2007;33(2):193-203. (Pubitemid 46385713)
73. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR, Paule MG, Slikker W Jr. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol. 1993;15(2):91-96. (Pubitemid 23128929)
74. Sprague JE, Everman SL, Nichols DE. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 1998;19(3):427-441.
75. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev. 2003;55(3):463-508. (Pubitemid 37013213)
76. Baumann MH, Wang X, Rothman RB. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl). 2007;189(4):407-424. (Pubitemid 44791212)
77. 11C]NMSP binding in living pig brain. Synapse. 2004;53(4):222-233.
78. Wang X, Baumann MH, Xu H, Morales M, Rothman RB. (±)-3,4- Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J Pharmacol Exp Ther. 2005;314(3):1002-1012. (Pubitemid 41205963)
79. Wang X, Baumann MH, Xu H, Rothman RB. 3,4-Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse. 2004;53(4):240-248. (Pubitemid 39045543)
80. Aghajanian GK, Hailgler HJ. Hallucinogenic indoleamines: preferential action upon presynaptic serotonin receptors. Psychopharmacol Commun. 1975;1(6):619-629.
81. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology. 1999;21(2)(suppl):16S-23S.
82. Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm. 2009;116(12):1591-1599.
83. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol. 2007;559(2-3):132-137. (Pubitemid 46295399)
84. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature. 2009;462(7270):175-181.
85. 2A receptor density in organotypic rat hippocampal cultures. Neurosci Lett. 2004;362(1):6-9.
86. 2A receptors by agonists and antagonists. Brain Res Bull. 2001;56(5):441-451.
87. Scheffel U, Lever JR, Stathis M, Ricaurte GA. Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors. Neuropharmacology. 1992;31(9):881-893.
88. Sundhedsstyrelsen. Ecstasy in Denmark 2008: report from the Department of Forensic Chemistry, Aarhus University, Denmark: report for the Danish National Board of Health. http://www.sst.dk/Udgivelser.aspx. 2009. Accessed March 2009.
89. Sundhedsstyrelsen. Ecstasy in Denmark 2007: report from the Department of Forensic Chemistry, Aarhus University, Denmark: report for the Danish National Board of Health. http://www.sst.dk/Udgivelser.aspx. 2008. Accessed December 2007.
90. Sundhedsstyrelsen. Narkotika på gadeplan [Narcotics in the streets] 2008: report from the Departments of Forensic Chemistry at Aarhus, Københavns, and Syddansk Universitet, Denmark: report for the Danish National Board of Health. http://www.sst.dk/Udgivelser.aspx. 2009.
91. Mash DC, Staley JK, Izenwasser S, Basile M, Ruttenber AJ. Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat. 2000;20(3-4):271-280. (Pubitemid 32162886)
92. Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, Nader MA. Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys. Neuropsychopharmacology. 2008;33(2):219-225. (Pubitemid 350243361)
93. Jacobsen LK, Staley JK, Malison RT, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB. Elevated central serotonin transporter binding availability in acutely abstinent cocaine- dependent patients. Am J Psychiatry. 2000;157(7):1134-1140. (Pubitemid 30432496)
94. Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang LC, Furukawa Y, Chang LJ, Wickham DJ, Sherwin A, Tong J. Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl). 2009;202(4):649-661.
95. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry. 2006;63(1):90-100. (Pubitemid 43037473)
96. Erritzoe D, Frokjaer VG, Haahr MT, Kalbitzer J, Svarer C, Holst KK, Hansen DL, Jernigan TL, Lehel S, Knudsen GM. Cerebral serotonin transporter binding is inversely related to body mass index. Neuroimage. 2010;52(1):284-289.